These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

425 related items for PubMed ID: 17540209

  • 1. Long-term effect of atorvastatin on neurohumoral activation and cardiac function in patients with chronic heart failure: a prospective randomized controlled study.
    Yamada T, Node K, Mine T, Morita T, Kioka H, Tsukamoto Y, Tamaki S, Masuda M, Okuda K, Fukunami M.
    Am Heart J; 2007 Jun; 153(6):1055.e1-8. PubMed ID: 17540209
    [Abstract] [Full Text] [Related]

  • 2. Atorvastatin therapy may reduce the incidence of sudden cardiac death in patients with advanced chronic heart failure.
    Vrtovec B, Okrajsek R, Golicnik A, Ferjan M, Starc V, Schlegel TT, Radovancevic B.
    J Card Fail; 2008 Mar; 14(2):140-4. PubMed ID: 18325461
    [Abstract] [Full Text] [Related]

  • 3. The influence of atorvastatin on parameters of inflammation and function of the left ventricle in patients with dilated cardiomyopathy.
    Bielecka-Dabrowa A, Goch JH, Mikhailidis DP, Rysz J, Maciejewski M, Banach M.
    Med Sci Monit; 2009 Dec; 15(12):MS12-23. PubMed ID: 19946241
    [Abstract] [Full Text] [Related]

  • 4. Long-term statin therapy in patients with systolic heart failure and normal cholesterol: effects on elevated serum markers of collagen turnover, inflammation, and B-type natriuretic peptide.
    Abulhul E, McDonald K, Martos R, Phelan D, Spiers JP, Hennessy M, Baugh J, Watson C, O'Loughlin C, Ledwidge M.
    Clin Ther; 2012 Jan; 34(1):91-100. PubMed ID: 22154198
    [Abstract] [Full Text] [Related]

  • 5. HMG CoA reductase inhibition and left ventricular mass in hypertrophic cardiomyopathy: a randomized placebo-controlled pilot study.
    Bauersachs J, Störk S, Kung M, Waller C, Fidler F, Hoyer C, Frantz S, Weidemann F, Ertl G, Angermann CE.
    Eur J Clin Invest; 2007 Nov; 37(11):852-9. PubMed ID: 17973781
    [Abstract] [Full Text] [Related]

  • 6. Plasma brain natriuretic peptide predicts short-term clinical outcome in heart failure patients with restrictive filling pattern.
    Feola M, Aspromonte N, Milani L, Bobbio M, Bardellotto S, Barro S, Giovinazzo P, Noventa F, Valle R.
    J Card Fail; 2008 Jun; 14(5):420-5. PubMed ID: 18514935
    [Abstract] [Full Text] [Related]

  • 7. Pleiotropic effects of atorvastatin in heart failure: role in oxidative stress, inflammation, endothelial function, and exercise capacity.
    Castro PF, Miranda R, Verdejo HE, Greig D, Gabrielli LA, Alcaino H, Chiong M, Bustos C, Garcia L, Mellado R, Vukasovic JL, Godoy I, Lavandero S.
    J Heart Lung Transplant; 2008 Apr; 27(4):435-41. PubMed ID: 18374881
    [Abstract] [Full Text] [Related]

  • 8. Effects of long-term treatment with pimobendan on neurohumoral factors in patients with non-ischemic chronic moderate heart failure.
    Sasaki T, Kubo T, Komamura K, Nishikimi T.
    J Cardiol; 1999 Jun; 33(6):317-25. PubMed ID: 10396705
    [Abstract] [Full Text] [Related]

  • 9. Baseline and serial neurohormones in patients with congestive heart failure treated with and without bucindolol: results of the neurohumoral substudy of the Beta-Blocker Evaluation of Survival Study (BEST).
    Frantz RP, Lowes BD, Grayburn PA, White M, Krause-Steinrauf H, Krishnan V, Uyeda L, Burnett JC, BEST Neurohumoral Substudy Investigators.
    J Card Fail; 2007 Aug; 13(6):437-44. PubMed ID: 17675057
    [Abstract] [Full Text] [Related]

  • 10. [Effects of phosphocreatine on plasma brain natriuretic peptide level in elderly patients with chronic congestive heart failure].
    Du XH, Liang FY, Zhao XW.
    Nan Fang Yi Ke Da Xue Xue Bao; 2009 Jan; 29(1):154-5, 159. PubMed ID: 19218138
    [Abstract] [Full Text] [Related]

  • 11. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency.
    Toblli JE, Lombraña A, Duarte P, Di Gennaro F.
    J Am Coll Cardiol; 2007 Oct 23; 50(17):1657-65. PubMed ID: 17950147
    [Abstract] [Full Text] [Related]

  • 12. The effects of atorvastatin (10 mg) on systemic inflammation in heart failure.
    Mozaffarian D, Minami E, Letterer RA, Lawler RL, McDonald GB, Levy WC.
    Am J Cardiol; 2005 Dec 15; 96(12):1699-704. PubMed ID: 16360360
    [Abstract] [Full Text] [Related]

  • 13. Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD.
    Koren MJ, Davidson MH, Wilson DJ, Fayyad RS, Zuckerman A, Reed DP, ALLIANCE Investigators.
    Am J Kidney Dis; 2009 May 15; 53(5):741-50. PubMed ID: 19216014
    [Abstract] [Full Text] [Related]

  • 14. Feasibility, safety, and mid-term efficacy of cardiac resynchronization therapy in patients with severe heart failure and ventricular conduction delay: Chulalongkorn experience.
    Sunsaneewitayakul B, Sitthisook S, Sangwatanaroj S, Prechawat S, Songmuang SB.
    J Med Assoc Thai; 2007 Jul 15; 90(7):1458-66. PubMed ID: 17710992
    [Abstract] [Full Text] [Related]

  • 15. Cutoff values of NT-proBNP for the prediction of low functional capacity, decreased ejection fraction and cardiovascular events in patients with heart failure.
    Koç M, Bozkurt A, Yildiray-Sahin D, Unal I, Acartürk E.
    Cardiol J; 2009 Jul 15; 16(1):43-9. PubMed ID: 19130415
    [Abstract] [Full Text] [Related]

  • 16. Early atorvastatin therapy improves cardiac function in patients with acute myocardial infarction.
    Teshima Y, Yufu K, Akioka H, Iwao T, Anan F, Nakagawa M, Yonemochi H, Takahashi N, Hara M, Saikawa T.
    J Cardiol; 2009 Feb 15; 53(1):58-64. PubMed ID: 19167639
    [Abstract] [Full Text] [Related]

  • 17. Management of elderly patients with congestive heart failure--design of the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF).
    Brunner-La Rocca HP, Buser PT, Schindler R, Bernheim A, Rickenbacher P, Pfisterer M, TIME-CHF-Investigators.
    Am Heart J; 2006 May 15; 151(5):949-55. PubMed ID: 16644310
    [Abstract] [Full Text] [Related]

  • 18. Double-blind, randomized, placebo-controlled study of high-dose HMG CoA reductase inhibitor therapy on ventricular remodeling, pro-inflammatory cytokines and neurohormonal parameters in patients with chronic systolic heart failure.
    Krum H, Ashton E, Reid C, Kalff V, Rogers J, Amarena J, Singh B, Tonkin A.
    J Card Fail; 2007 Feb 15; 13(1):1-7. PubMed ID: 17338996
    [Abstract] [Full Text] [Related]

  • 19. [The clinical value of B-type natriuretic peptide in the diagnosis of left heart failure].
    Zhao XY, Yang YJ, Zhang J, Dang AM, Ni XH, Huang J, Kang S, Ma WH, Zhao DY.
    Zhonghua Yi Xue Za Zhi; 2006 May 09; 86(17):1165-9. PubMed ID: 16796855
    [Abstract] [Full Text] [Related]

  • 20. Beta-erythropoietin effects on ventricular remodeling, left and right systolic function, pulmonary pressure, and hospitalizations in patients affected with heart failure and anemia.
    Palazzuoli A, Silverberg DS, Calabrò A, Spinelli T, Quatrini I, Campagna MS, Franci B, Nuti R.
    J Cardiovasc Pharmacol; 2009 Jun 09; 53(6):462-7. PubMed ID: 19455052
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.